Dashboard
Manage Tickers

CBAY


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Gilead Sciences Completes Of Acquisition O...
03/22/2024 13:21:50

gileads-aggressive-push-beyond-hiv-treatments---plans-to-increase-cancer-focused-car-t-treatment-production
Gilead's Aggressive Push Beyond HIV Treatm...
03/15/2024 16:51:50

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yesc...

top-3-health-care-stocks-that-are-ticking-portfolio-bombs
Top 3 Health Care Stocks That Are Ticking ...
03/14/2024 12:57:27

As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum a...

cymabay-announces-european-medicines-agency-accepts-for-review-the-marketing-authorization-application-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis
CymaBay Announces European Medicines Agenc...
03/04/2024 13:22:32

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver a...

hc-wainwright--co-reiterates-neutral-on-cymabay-therapeutics-maintains-325-price-target
HC Wainwright & Co. Reiterates Neutral on ...
02/29/2024 14:07:45

HC Wainwright & Co. analyst Ed Arce reiterates CymaBay Therapeutics (NASDAQ:CBAY) with a Neutral and maintains $32.5 pri...

cymabay-therapeutics-q4-eps-035-misses-031-estimate
CymaBay Therapeutics Q4 EPS $(0.35) Misses...
02/28/2024 22:15:29

CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate o...

leerink-partners-downgrades-cymabay-therapeutics-to-market-perform-announces-325-price-target
Leerink Partners Downgrades CymaBay Therap...
02/20/2024 10:05:33

Leerink Partners analyst Thomas Smith downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform and an...

lifesci-capital-downgrades-cymabay-therapeutics-to-market-perform
LifeSci Capital Downgrades CymaBay Therape...
02/14/2024 13:21:19

LifeSci Capital analyst Cory Jubinville downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform.

piper-sandler-downgrades-cymabay-therapeutics-to-neutral-lowers-price-target-to-325
Piper Sandler Downgrades CymaBay Therapeut...
02/14/2024 11:11:56

Piper Sandler analyst Yasmeen Rahimi downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Overweight to Neutral and lowers the...

cymabay-therapeutics-deal-may-not-be-needle-moving-for-100b-valued-gilead-but-acquisition-is-reasonably-priced-analyst
CymaBay Therapeutics Deal May Not Be Needl...
02/13/2024 19:05:04

Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potenti...

btig-downgrades-cymabay-therapeutics-to-neutral
BTIG Downgrades CymaBay Therapeutics to Ne...
02/13/2024 13:16:37

BTIG analyst Julian Harrison downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Buy to Neutral.

hc-wainwright--co-downgrades-cymabay-therapeutics-to-neutral
HC Wainwright & Co. Downgrades CymaBay The...
02/13/2024 12:57:08

HC Wainwright & Co. analyst Ed Arce downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Buy to Neutral.

cantor-fitzgerald-downgrades-cymabay-therapeutics-to-neutral-announces-325-price-target
Cantor Fitzgerald Downgrades CymaBay Thera...
02/13/2024 10:51:55

Cantor Fitzgerald analyst Kristen Kluska downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Overweight to Neutral and announ...

jonestrading-downgrades-cymabay-therapeutics-to-hold
JonesTrading Downgrades CymaBay Therapeuti...
02/13/2024 10:49:57

JonesTrading analyst Sean Kim downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Buy to Hold.

fear--greed-index-remains-in-extreme-greed-zone-ahead-of-inflation-data-dow-hits-record-high
Fear & Greed Index Remains In 'Extreme Gre...
02/13/2024 08:43:42

The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday,...

dow-surges-over-150-points-gilead-sciences-to-acquire-cymabay-therapeutics-for-43b
Dow Surges Over 150 Points; Gilead Science...
02/12/2024 17:30:46

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded u...

william-blair-downgrades-cymabay-therapeutics-to-market-perform
William Blair Downgrades CymaBay Therapeut...
02/12/2024 16:44:08

William Blair analyst Andy Hsieh downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform.

cymabay-therapeutics-contextlogic-snap-and-other-big-stocks-moving-higher-on-monday
CymaBay Therapeutics, ContextLogic, Snap A...
02/12/2024 15:22:57

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ...

health-care-company-gilead-sciences-announces-acquisition-of-cymabay-therapeutics
Health Care Company Gilead Sciences Announ...
02/12/2024 15:10:05

drugmaker-gilead-sciences-scoops-up-liver-disease-focused-cymabay-therapeutics-for-43b
Drugmaker Gilead Sciences Scoops Up Liver-...
02/12/2024 14:22:54

Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA prio...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION